DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Hill S, Khullar V, Wyndaele JJ. et al.
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Int Urogynecol J Pelvic Floor Dysfunct 2006;
17: 239-247
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.